1/ It's long been assumed that AEBP2 recruit PRC2 to chromatin. Now, we show that AEBP2 usually does the exact opposite: The only isoform of AEBP2 that is expressed in most cell types and tissues inhibits the chromatin-binding activity of PRC2. www.embopress.org/doi/full/10....

1/ 🚀 AEBP2 isn’t what we thought. You were told that AEBP2 promotes PRC2 activity on chromatin. We found the opposite: the most prevalent AEBP2 isoform inhibits PRC2 activity. 👉 surl.li/cgwqcq A thread 🧵

Very happy to see our paper published online natcomms.nature.com. Thank you to @wellcometrust.bsky.social for funding this work during my time with @robklose.bsky.social and David Booth! Thanks also to collaborators @garcialabms.bsky.social @alexdemendoza.bsky.social and the other authors!

Pleased to present at #ESMO25 the 16 year experience of tandem high-dose chemotherapy and autologous stem cell transplant for relapsed/refractory advanced stage germ cell tumours from Princess Margaret Cancer Centre, Toronto 🇨🇦

🧵1/Exciting news in cancer epigenetics! Our latest research, "AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma", is now available on www.biorxiv.org/content/10.1.... Here's a thread summarizing our findings!👇 #CancerResearch #Epigenetics #Chromatin #Lymphoma

Excited to share our new paper out today in @cp-molcell.bsky.social! We show that the H3K27M oncohistone rewires cPRC1, creating a unique dependency on CBX4/PCGF4-containing complexes, and also reveal a previously unknown function of CBX4. Highlights below (1/11).

Our work identifying CBX4 as a potential therapeutic target for diffuse midline glioma has just been published in Molecular Cell! Check out co-first author @eimearlagan.bsky.social’s overview below.

🧵 1/ We’re excited to share that our new paper with @adrianbracken.bsky.social lab is out 🎉 In this study (which began over 10 years ago!), we explore the biology of PRC2 and PRC1 in non-dividing cells. We also explore the effects of PRC2 inhibitor drugs on these cells. Here’s what we found👇

Congrats to @jamesnolan.bsky.social (now at @pmresearch-uhn.bsky.social) on his #ASH24 abstract achievement award for his PhD research @tcddublin.bsky.social! @adrianbracken.bsky.social 🇮🇪🇨🇦 @ash-hematology.bsky.social #Lmsm #ASHKudos

Looking forward to sharing collaborative work by myself and @dr-chromatin.bsky.social from the labs of @adrianbracken.bsky.social and @conwayer1.bsky.social at #ASH24 in San Diego this week. #hemesky #lymsm please feel free to stop by and share your thoughts.

🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼 PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼 A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼 doi.org/10.1182/bloo... #MedSky #HemeSky

How does PRC1 counteract transcription? See this preview from @adrianbracken.bsky.social and I on an exciting new study from @robklose.bsky.social lab where they show ncPRC1 blocks the early stages of transcription. www.sciencedirect.com/science/arti... @conwayer1.bsky.social for title inspo!

My colleague @fergutierrezro1 giving an excellent talk at #ESHBMFS2024 on the clinical implications of clonal hematopoiesis in #telomere biology disorders 🧬; dependent on specific mutation with U2AF1, TP53, and chr1+ associated with #MDSsm and #AMLsm.